Drug Type Fusion protein |
Synonyms |
Target |
Mechanism IL2RA agonists(Interleukin-2 receptor alpha chain agonists), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 3 | GB | - | 06 Nov 2019 |
Neoplasms | Preclinical | - | - |